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ReviewSummary
The incidence of hepatocellular carcinoma (HCC) is increasing in industrialised societies; this is likely
secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD), its progressive form non-
alcoholic steatohepatitis (NASH), and the metabolic syndrome. Cumulative studies suggest that NAFLD-
related HCC may also develop in non-cirrhotic livers. However, prognosis and survival do not differ
between NAFLD- or virus-associated HCC. Thus, research has increasingly focused on NAFLD-related risk
factors to better understand the biology of hepatocarcinogenesis and to develop new diagnostic, pre-
ventive, and therapeutic strategies. One important aspect thereof is the role of hepatokines and adipo-
kines in NAFLD/NASH-related HCC. In this review, we compile current data supporting the use of
hepatokines and adipokines as potential markers of disease progression in NAFLD or as early markers of
NAFLD-related HCC. While much work must be done to elucidate the mechanisms and interactions
underlying alterations to hepatokines and adipokines, current data support the possible utility of these
factors – in particular, angiopoietin-like proteins, fibroblast growth factors, and apelin – for detection or
even as therapeutic targets in NAFLD-related HCC.
© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Hepatocellular carcinoma (HCC) is the third most
common cause of cancer-related mortality world-
wide, and the most common primary liver cancer.1
The incidence of HCC increased by 3.1% per year
between 2008 and 2012.2 Growing epidemiologic
evidence indicates an association between non-
alcoholic fatty liver disease (NAFLD) and the risk
of HCC development. The incidence of HCC among
patients with NAFLD is around 0.44 per 1,000
person-years (range: 0.29–0.66).3
The pathogenic mechanisms linking NAFLD/
non-alcoholic steatohepatitis (NASH) to HCC
remain poorly understood (Fig. 1). Although
cirrhosis is the major risk factor for HCC develop-
ment,4,5 a significant portion of NASH-related HCC
develops in livers with no or minimal liver
fibrosis.6 Among individuals without cirrhosis,
those with NASH are at a higher risk of HCC than
those with other liver diseases.7 In 500 patients
with HCC of various aetiologies, 43% had cirrhosis.8
In particular, cirrhosis was present in only 23% of
NAFLD-related and 21% of NASH-related HCC.8 We
reported that of 162 adults with HCC, cirrhosis was
present in 58.3% of those with NAFLD-related HCC;
by contrast, cirrhosis was seen in nearly 90% of
patients with non-NASH and non-cryptogenic
HCC.9 In a US Veterans Health Administration
cohort of 1,500 patients, about 87% had cirrhosis.
Among patients with NAFLD-related HCC onlyJournal of Hepatology 2021 vol. 74 j 465.4% had evidence of cirrhosis. The risk of devel-
oping HCC in a non-cirrhotic liver was increased
5.4-fold for NAFLD and 5-fold for metabolic syn-
drome (MetS) compared to HCV.10 In 77 patients
with non-viral-associated HCC, 30% of NAFLD-
related HCC cases developed in patients with no
or minimal fibrosis.6,11 Collectively, these results
suggest that HCC in NAFLD can develop at any
stage of hepatic fibrosis,6,10,11 with 20–50% of
NAFLD-related HCC occurring in non-cirrhotic
cases. This wide range could be explained by het-
erogeneous methods and protocols to assure or
exclude cirrhosis. Most patients with NAFLD
without symptoms do not undergo liver biopsy,
leading to a substantial underdiagnosis of
compensated cirrhosis.12 However, given the cur-
rent understanding of HCC in non-cirrhotic NAFLD,
we cannot exclude that the development of HCC
may start at early stages of NAFLD.13–15
The prevalence of NAFLD has increased world-
wide in parallel with the rising tide of obesity,
MetS, and type 2 diabetes mellitus (T2DM).16,17 In
MetS-related HCC (MetS-HCC), tumours are often
larger and well differentiated compared to non-
MetS-HCC (65% vs. 28%, p <0.001). While 74% of
patients with non-MetS-HCC have bridging fibrosis
or cirrhosis (F3-F4), only 35% of patients with
MetS-HCC have significant fibrosis (65% non-






NAFLD is the most com-
mon cause of chronic liver
disease worldwide. The
prevalence of NASH, the
severe variant of NAFLD, is
rising in parallel with the
epidemics of obesity and
type 2 diabetes mellitus.
Key point
HCC is a leading cause of
cancer-related death in the
general population, and it
is estimated that the
occurrence of NASH-
related HCC will increase
continually following the
still ongoing increase of
NAFLD prevalence.with HCC, the prevalence of NASH was significantly
higher in the MetS-HCC group than the matched
HCV-HCC group (25.0% vs. 9.4%, p = 0.004).19 90-
day morbidity and liver failure rates were similar
in MetS-HCC and HCV-HCC, and were impacted by
the presence of cirrhosis, major hepatectomy, and a
model for end-stage liver disease (MELD) score of
>8, but not by NASH. Overall 5-year survival was
significantly higher in the MetS-HCC group (65.6%
vs. 61.4%, p = 0.031).19,20 Additionally, inflammatory
hepatocellular adenoma, which may undergo ma-
lignant transformation, is likewise associated with
obesity, steatosis and MetS – hence constituting
another risk factor for HCC development in non-
cirrhotic livers.6,18,21,22
Overall, the mechanisms of HCC development in
NAFLD remain uncertain and merit in-depth
investigation at the molecular level. In this
context, hepatokines and adipokines have been
gaining much attention in recent years. Herein, we
will review the current understanding of how
hepatokines and adipokines affect the pathogen-
esis of NASH-related HCC.
Risk factors and the pathogenesis of NASH
and NASH-related HCC
Obesity results from excess calorie uptake due to an
unhealthy diet (i.e. high calorie diet) and a sedentary
lifestyle, combined with the complex interplay be-
tween genes and the environment.16 Obesity-related
chronic inflammation is associated with increased
proinflammatory cytokines such as tumour necrosis
factor-a (TNF-a) and interleukin-6 (IL-6),23 and an
imbalanced adipokine profile.24,25 Other effects of
obesity include increased reactive oxygen species
(ROS), endoplasmic reticulum (ER) stress and acti-
vation of NF-jB, resulting in inhibition of apoptosis
in the liver.23,26 ER stress in the liver augments the
unfolded protein response, and NOD-like receptor
P3 (NLRP3) inflammasome pathway stimulation27,28
as well as hepatic insulin resistance (IR). These
multifactorial effects of obesity not only favour lipid
storage and inflammation but also tumour devel-
opment in the liver. Obesity is generally associated
with cancer growth.29 The increased risk of HCC
development observed in obesity probably results
from interactions between the aforementioned ef-
fects: Prevention of apoptosis, i.e. due to ROS and ER
stress, can promote tumour cell proliferation,30,31
while free fatty acid (FFA)-induced and ER-stress-
enhanced NLRP3 activation27,28 results in disrupted
insulin signalling and IR.28
As described, IR is associated with overweight
and obesity and is considered a key pathophysio-
logical mechanism for development of NAFLD,
NASH and MetS.32–35 In patients with IR, increased
release of lipids and FFAs from adipose tissue into
the blood leads to ectopic fat deposition in the liver
and other organs.36 IR results in continued highJournal oblood glucose levels and in T2DM in the long term.
NAFLD is independently associated with an
increased incidence of T2DM.37,38 Conversely,
T2DM increases the risk of HCC development 2- to
3-fold39 and IR might be the common underlying
risk factor.40,41
Obesity and NAFLD are both closely associated
with MetS and a complex change of multiple
cellular mechanisms, metabolic pathways, and in-
flammatory activity in adipose tissue and the liver.
However, many of these processes cannot currently
be utilised for the detection or diagnosis of HCC
development in NAFLD.
Do hepatokines and adipokines influence
NASH-related HCC?
Liver and adipose tissue release organ-specific cy-
tokines, termed hepatokines and adipokines, with
autocrine, paracrine, and endocrine functions. Both
hepatokines and adipokines have potent effects on
metabolic homeostasis42 and are candidate bio-
markers for the diagnosis or monitoring of meta-
bolic diseases.43
Hepatokines play a central role in orchestrating
whole-body energy metabolism as the liver adapts
their secretion in response to stress signals (IR,
T2DM, NASH). Hepatocytes in culture secrete more
than 500 proteins.44,45 However, only few have
been studied as hepatokines and only a fraction –
such as hepassocin, fetuins A and B and fibroblast
growth factor 21 (FGF21) – have been linked to
obesity and IR45 and their role in the development
of NAFLD- and NASH-related HCC remains unclear.
It has been established that adipokines play a
crucial role in adipogenesis and in obesity-related
diseases such as NAFLD.46 Herein, we aim to pro-
vide an overview of the current knowledge on
hepatokines (Table 1) and adipokines (Table 2)




Angiopoietin-like proteins (ANGPTLs) are circu-
lating hepatokines that act on angiogenesis,
inflammation and carcinogenesis.47 Specifically,
ANGPTL3, -4, -6 and -8 affect lipoprotein meta-
bolism and the regulation of plasma lipid levels –
the latter by inhibiting extracellular lipases;48
ANGPTL1, -2 and -8 have diverse roles in HCC
tumorigenesis. To date, the role of the ANGPTLs in
NASH-related HCC remains to be elucidated.
In obese patients, fasting was found to decrease
serum ANGPTL3 but increase ANGPTL4 levels, and
only ANGPTL3 was reduced after a very low calorie
diet.49 ANGPTL3 directly inhibits lipoprotein lipase
(LPL).48 ANGPTL4 is mainly expressed in the liver
and adipose tissues, contributes to inhibition of





• ≥60% of NAFLD
• Hepatic steatosis ≥ 5%
• Without inflammation





• 25-40% of NAFLD
• Hepatic steatosis ≥5%
• Hepatocyte ballooning
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Fig. 1. Associations of obesity and risk factors for NAFLD and NASH-related-HCC with hepatokines and adipokines. (A) Overview of generally known risk
factors for NAFLD and NAFLD-related HCC and natural history of NAFLD. Obesity constitutes a risk factor for development of NAFLD, IR, hyperlipidaemia, and
hypertension. These are components of the MetS, with NAFLD the hepatic manifestation. NAFLD ranges from simple hepatic steatosis (NAFL) to NASH, which is
characterised by the presence of inflammation and hepatocyte ballooning with or without fibrosis. While NAFL is a risk for IR, NASH also constitutes a risk factor
for progression from IR to T2DM and vice versa. NASH also increases the risk of hyperlipidaemia and hypertension. Approximately 60% of NAFLD cases are NAFL,
while NASH occurs in 25–40%. Of patients with NASH, 25–35% develop simple to mild fibrosis. Cirrhosis and cirrhotic HCC are found in 9–20% of patients with
NASH. Approximately 0.5% of the patients with NAFLD and 2.8% of the patients with NASH develop HCC.26 Red arrows indicate a risk for the target condition;
black arrows indicate a possible development/progression of the target condition. (B) Known regulations of hepatokines and adipokines during obesity and
different stages of NAFLD. Black up-arrow: upregulated in condition; Black down-arrow: downregulated in condition; red arrow: (increased) hepatokine or
adipokine facilitates or increases risk of developing target condition; green arrow: (increased) hepatokine or adipokine blocks or reduces risk of developing target
condition. ANGPTL, angiopoietin-like protein; FGF, fibroblast growth factor; HCC, hepatocellular carcinoma; IR, insulin resistance; MetS, metabolic syndrome;
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; RBP4, retinol-binding protein 4; T2DM, type 2 diabetes mellitus.
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Reviewhumans, under physiological conditions such as
fasting, cold exposure, and exercise, the fatty acid-
activated peroxisome proliferator-activated re-
ceptors (PPARs) regulate ANGPTL4 expression.48,50
ANGPTL6 (also known as angiopoietin-related
growth factor, or AGF) is a hepatocyte-derived
circulating factor that inhibits the development ofJournal of Hepatology 2021 vol. 74 j 4obesity and IR.51 Serum levels of ANGPTL6 posi-
tively correlate with fasting glucose in T2DM,51,52
and with the intake of vitamin D in obese
individuals.53
ANGPTL8/betatrophin (also known as HCC
associated protein, TD26, or lipasin)54,55 is
expressed primarily in liver and visceral adipose42–457
Table 1. Overview of secreted proteins usually described as hepatokines.
Factor Known effects Site(s) of expression Target site(s) References
ANGPTL1  In vitro Inhibition of the HGF receptor
 In vitro suppression of motility and metastasis of
hepatoma cells
 Serum concentrations inversely correlated to
clinical outcome in HCC
Vascularised tissue Vascular endothelial cells 47,63
ANGPTL2  Increased expression in HCC and positive correlation
with intrahepatic metastasis in HCC
Hepatocytes Endothelial cells 47,64
ANGPTL3  Decreased serum concentrations during fasting in
obesity
 Inhibits lipoprotein lipase
Hepatocytes Adipocytes 48,49
ANGPTL4  Increased serum concentrations during fasting in
obesity
 Low expression in HCC liver tissue compared to
non-tumourous tissue
 Suppression of tumorigenesis and metastasis in
murine HCC models




ANGPTL6  Increased serum ANGPTL6 levels in T2DM and
with intake of vitamin D in obesity






ANGPTL8  Increased serum levels associated with the presence of
liver steatosis and increased plasma triglyceride levels
 Decreased serum levels in the development of MetS
 Increased serum levels in IR, in impaired glucose
regulation and T2DM
 Increased lipogenesis and proliferation in HCC
by ANGPTL8
 Increased expression in HCC liver tissue, correlation
with tumour size
Liver tissue and VAT Probably multiple target
cell types, including autocrine
effects
48,55–59,62
Fetuin-A  Increased serum levels in obesity, T2DM, MetS, NAFLD
 Correlation with liver fibrosis stage in NAFLD
Hepatocytes Carrier protein (i.e. for fatty
acids); adipocytes, muscle cells
42,66–68,70,76
Fetuin-B  Increased serum levels in liver steatosis and T2DM
 Negative correlation with non-invasive markers of liver
fibrosis in NAFLD
Hepatocytes Carrier protein; multiple
target tissues (i.e. neurons,
adipocytes, hepatocytes)
75,77
FGF1  Increased FGF1 levels in obesity Hepatic stellate cells, adipocytes Auto-and paracrine targeting
of adipocytes; hepatic stellate
cells, hepatocytes
82,85
FGF2  Increased FGF2 levels in obesity
 Increased serum FGF2 levels in liver cirrhosis and HCC
Hepatic stellate cells, adipocytes,
hepatocytes





 Increased FGFR4-mediated signalling and reduced serum
FGF19 in NAFLD
 Modestly increased serum FGF19 and FGFR4 in
NASH patients with advanced ballooning
 Increased FGF19 levels in diabetic obese and NASH
patients with T2DM remission and NAFLD
improvement after sleeve gastrectomy
 FGF19 analogue reduces liver fat content in NASH
 FGFR4 polymorphisms in patients with cirrhosis and HCC
 Increased hepatic FGF19/FGFR4 expressions and serum
levels associated with poor outcome in HCC
 Increased FGF19/FGFR4 expressions together with EpCam
in the progression of fatty liver (NAFLD) to HCC
 Increased serum b-Klotho proteins in HCC
Ileum, Liver, adipocytes, possibly
cholangiocytes
Mature hepatocytes 90–93,95–97,230,231
FGF21  Increased serum FGF21 levels in obesity, NAFLD,
MetS, and T2DM
 Positive correlation between liver FGF21 expression and
adiposity, fasting insulin, intrahepatic triglycerides, and
negative correlation with HDL cholesterol and BMI
 Possible independent risk factor for progression to NASH
 Increased serum FGF21 levels in liver cirrhosis and HCC
Liver, adipocytes, pancreas Adipocytes, hypothalamus 101–104,106
Hepassocin
(HPS)
 Increased serum levels in NAFLD and correlation
with NAS
 Low hepassocin expression in HCC
Liver T-cells 107,108,114
RBP4  Controversial results for serum RBP4 and
expression levels in NAFLD
 Increased liver RBP4 protein expression in fibrosis, high
lobular inflammation and NAS in NASH
 Increased serum RBP4 levels and expressions in
adipocytes in obesity
 Decreased serum and hepatic RBP4 levels in liver
cirrhosis correlated with reduced hepatic
glucose production
Hepatocytes, adipocytes Retinol delivery to diverse
peripheral tissues (i.e. retina)
120–128,232,233
Known effects and target sites in metabolic diseases (obesity, IR, T2DM, MetS, NAFLD, NASH) and HCC. ANGPTL, angiopoietin-like protein; FGF, fibroblast growth factor; HCC,
hepatocellular carcinoma; IR, insulin resistance; MetS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NAS, NAFLD activity
scores; RBP4, retinol-binding protein 4; T2DM, type 2 diabetes mellitus; VAT, visceral adipose tissue.
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Table 2. Overview of secreted proteins usually described as adipokines.
Factor Known effects Site(s) of expression Target site(s) References
Adiponectin  Decreased serum HMW adiponectin levels in obesity,
advanced NAFLD and NASH patients with advanced
ballooning, IR, T2DM, cardiovascular disease and MetS
 Decreased serum adiponectin levels in HCC
 Negative correlation with tumour size in HCC and with
higher risk of HCC
 Increased adiponectin levels in cirrhotic hepatitis virus
infected-HCC patients
 Adiponectin serum concentrations are an independent
predictor of overall survival in HCC patients
Adipocytes Hepatocytes, hepatic stellate
cells, muscle cells, probably
more target cell populations
(i.e. brain)
78,91,136–142,159–163
Apelin  Increased serum apelin levels in obesity in NAFLD patients
 Apelin contributes to the angiogenesis of liver tissue in NASH
 Increased apelin expression in HCC and correlation with
tumorigenicity in HCC
 Apelin stimulates arteriogenesis in HCC
 Increased apelin receptor expression in the presence of
microvascular invasion, intrahepatic metastasis, and early
recurrence independent of HCC aetiology




Chemerin  Association between increased serum chemerin levels and
NAS, and with the presence of hepatocyte ballooning and
inflammatory activity
 Decreased chemerin VAT expression in high NAS score and
after weight loss and/or bariatric surgery
 Correlation between low serum chemerin levels and hepatic
dysfunction, increased mortality in patients with
decompensated cirrhosis and ascites
 Independent prognostic factor in HCC, but no correlation
with recurrence or prognosis in HCC patients
 Association between increased serum chemerin with a poor
prognosis of HCC
Adipocytes, hepatocytes 178–181,187–192
Leptin  Increased serum leptin levels in obesity, T2DM, NASH and
NAFL, but no significant predictor of NASH vs. non-NASH
 Increased serum leptin levels in cirrhosis independent of HCC
 Increased serum leptin levels are a risk factor for recurrent
phase I/II of HCC after curative treatment
 Increased serum leptin levels in cirrhotic patients with or
without HCC vs. controls








Resistin  Increased serum resistin levels in morbidly obese patients
and T2DM
 Independent risk factor and marker to identify HCV-related
cirrhosis vs. HCV-related HCC development
Adipose tissue Hepatocytes 212,213,218
Visfatin  Increased serum visfatin levels in NAFLD
 Increased visfatin liver expression in morbidly obese
patients with T2DM.
 No correlation between liver visfatin expression, NAS score,
and inflammatory stages in obese patients with NAFLD
 Association between increased visfatin levels and poor
prognosis, stage progression and tumour enlargement
in HCC
 Increased liver expression in liver fibrosis and cirrhosis
 Increased serum visfatin levels in viral-HCC






Known effects and target sites in metabolic diseases (obesity, IR, T2DM, MetS, NAFLD, NASH) and HCC. HCC, hepatocellular carcinoma; HMW, high molecular weight; IR,
insulin resistance; MetS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NAS, NAFLD activity scores; T2DM, type-2
diabetes mellitus; VAT, visceral adipose tissue.
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Reviewtissue (VAT), and is associated with liver steatosis
and increased plasma triglyceride levels in
humans.55,56 Serum levels of ANGPTL8 are signifi-
cantly increased in IR57 and T2DM.58,59 ANGPTL8
requires ANGPTL3 to act on LPL, while ANGPTL8
alone has no demonstrable effect on LPL.60 When
brown adipose tissue (BAT) is exposed to the cold,
overexpression of ANGPTL8 (and decreased
ANGPTL4) upregulates LPL activity and triglyceride
uptake.60,61 A significant correlation betweenJournal of Hepatology 2021 vol. 74 j 4decreased serum ANGPTL8 levels and the devel-
opment of MetS was also observed.62
Studies in human tissues and cell lines revealed
diverging roles of different ANGPTLs in HCC. For
example, ANGPTL1 suppressed Snail family of
C2H2-type zinc finger transcription factor SNAI2
expression, which reduced cancer cell motility and
metastasis and competed with hepatocyte growth
factor for binding to the MET receptor in HCC
cell lines; in addition, ANGPTL1 expression was42–457
inversely correlated with poor clinical outcomes in
HCC.63 ANGPTL2 expression was higher in HCC
tissues compared with matched non-cancerous
liver tissues, and positively correlated with intra-
hepatic metastasis in patients with HCC.64
ANGPTL4 expression was lower in HCC tissue
than non-tumorous liver tissue65 and full-length
ANGPTL4-overexpression in mice suppressed HCC
tumorigenesis and metastasis.65 ANGPTL8 was
significantly overexpressed in HCC, and ANGPTL8
positively correlated with the tumour size in
HCC.55 Lipogenesis and proliferation in HCC are
also increased by ANGPTL8 through its interaction
with nuclear sterol regulatory element-binding
protein-1 (SREBP-1).55 Altogether, ANGPTL
profiling in patients with NASH could identify pa-
tients at risk of HCC but further evaluation in larger
studies is required.
Fetuins A and B
Fetuin-A (also known as a2-HS-glycoprotein) was
the first hepatokine shown to be associated with
metabolic disease. Serum levels are increased in
obesity,42,66 and it is an early biomarker of
NAFLD,67,68 MetS, IR69 and T2DM.70 Fetuin-A was
identified as an endogenous Toll-like receptor 4
(TLR4)-ligand in lipid-induced IR.71 Secretion of
fetuin-B by hepatocytes has also been described in
liver steatosis and T2DM.44,45 Hepatic expression of
both fetuins A and B increased in hepatic steatosis
in humans.69 However, only weak correlations
were observed between hepatic and serum con-
centrations of fetuins A and B.69 Human studies
have meanwhile established that fetuin-A induces
IR in concert with FFA via TLR4.45,69,72 Most data on
fetuin-B derive from in vitro or animal studies
which show that it may reduce insulin sensitivity
but could actually cause glucose intolerance.72,73
Treatment of HepG2 cells with recombinant
fetuin-B increased hepatic lipid accumulation,
while loss of fetuin-B inhibited hepatocellular lipid
accumulation, improved glucose metabolism,44,74
and reduced intrahepatic and serum triglyceride
contents in mice.75 Fetuin-B seems to reduce
phosphorylation of 5’adenosine monophosphate-
activated protein kinase (AMPK) and to inhibit LXR-
SREBP1c-dependent lipogenesis, while increasing
fatty acid oxidation in vitro and in vivo in mice.75 In
patients with NAFLD, serum levels of both fetuins A
and B negatively correlatedwith liver fibrosis stage76
and other markers of liver fibrosis.77 High serum
fetuin-A concentrations were also detected in pa-
tients with HCC.78 Taken together fetuin-A and B
seem to negatively affect insulin sensitivity and
glucose tolerance, suggesting a role in NAFLD and
probably NAFLD-related HCC via IR.
Fibroblast growth factors
Fibroblast growth factors (FGFs) are secreted
signalling proteins which regulate energy meta-
bolism.79 Canonical FGF functions comprise controlJournal oof cell proliferation, differentiation and sur-
vival.80,81 The FGF family includes 7 subfamilies
with 18 secreted FGFs, which interact with 4
tyrosine kinase FGF receptors (FGFRs) via different
cofactors.82 FGFs bind heparin (mainly paracrine
FGFs) – except for the FGF19 subfamily (FGF19,
FGF21, and FGF23), which requires the Klotho
proteins as cofactors (mainly endocrine FGFs).82,83
Hepatic stellate cells (HSCs) play a pivotal role in
liver fibrosis84 and are activated by neighbouring
cells and secreted factors. FGFs produced by HSCs –
i.e. FGF1, FGF2, FGF7, FGF15, FGF9 – bind FGFRs on
hepatocytes.82 Some FGFs (FGF1, FGF2, FGF7,
FGF19, FGF18 and FHF2 [previously known as
FGF13]) are also expressed in subcutaneous white
adipose tissue (scWAT).85 The particular functions
of FGFs depend on the FGF/FGFRs and the expres-
sion of heparin/klotho proteins in target tis-
sue.83,85,86 Here, we briefly discuss the most
relevant FGFs relating to human metabolism and
liver disease.
FGF1 and FGF2 are involved in HSC activation.82
One study mapped the expression and secretion of
FGFs in scWAT from non-obese and obese in-
dividuals.85 Apparently only FGF1 is produced in
adipocytes and acts as an auto- and paracrine fac-
tor. Only the levels of FGF1 and FGF2 significantly
differed between non-obese and obese female in-
dividuals. While FGF1 expression levels were
doubled among obese individuals compared to
non-obese controls, FGF2 expression in scWAT was
significantly reduced.85 Serum FGF2 levels were
also found to be increased in cirrhosis and HCC.87
In the liver and adipocytes, endocrine FGF19
and FGF21 activate FGFR4 and FGFR1c together
with cofactor b-Klotho, which is abundantly
expressed in hepatocytes. FGF19 and FGF21 control
bile acid, lipid and glucose metabolism.88,89 FGFR4
is predominantly expressed in mature hepato-
cytes.90 In a study in humans, serum FGF19 and
FGFR4 levels paralleled those of serum bile acids
and were significantly increased in patients with
NASH and advanced ballooning.91 In patients with
NAFLD, serum concentrations of primary and sec-
ondary bile acids were increased as a result of
impaired FXR and FGFR4-mediated signalling.92,93
Recently, a multicentre, randomized, double-
blinded, placebo-controlled, phase II trial was
performed to test the safety and efficacy of an
FGF19 analogue for patients with NASH (NAFLD
activity score [NAS] >−4, fibrosis stage: 1–3; liver fat
>−8%). Twelve weeks of treatment led to a rapid and
significant reduction in the amount of liver fat.94
FGFR4 polymorphisms have also been detected in
patients with cirrhosis and HCC95 and the over-
expression of hepatic and serum FGF19/FGFR4 has
been associated with poor outcomes in patients
with HCC.93,96,97 This was confirmed by our own
group, demonstrating increased serum FGF19 in
NASH, NASH-HCC and in particular cirrhotic NASH-
HCC.98 FGF19 was also correlated with alterationsf Hepatology 2021 vol. 74 j 442–457 447
Key point
While a significant number
of individuals with NAFLD
develops HCC without





Reviewin bile acids and tumour markers. The b-Klotho
proteins are also increased in the serum and livers
of patients with HCC as a result of ER stress.93,97
The hepatokine FGF21 is a regulator of glucose
and lipid homeostasis and a stress response hor-
mone. FGF21 has a positive effect on hepatic stea-
tosis, enhances lipid oxidation, suppresses de novo
lipogenesis in the liver,99 and improves IR by
inhibiting mTOR.100 Serum FGF21 levels are
significantly increased in overweight/obese pa-
tients101 and in those with NAFLD,102 MetS,101
T2DM103 as well as HCC and cirrhosis.104 Liver
FGF21 expressions were positively correlated with
adiposity, fasting insulin and intrahepatic tri-
glycerides,101,102 but negatively correlated with
HDL cholesterol and BMI.101 Elevated serum FGF21
levels were also independently associated with an
increased risk of developing MetS.101 These results
were consistent with a study in obese children
with and without NAFLD. Serum FGF21 concen-
trations were significantly higher in obese children
with NAFLD and were positively correlated with
steatosis grades (severe vs. mild) in biopsies and
with the total intrahepatic lipid content assessed
by magnetic resonance proton spectroscopy.105
Serum FGF21 levels positively correlated with
NAS and pathological characteristics of NAFLD;
patients with advanced NASH could be identi-
fied by FGF21 serum levels in combination with
cytokeratin-18-M30 antigen, IL-1Ra, pigment
epithelium-derived factor and osteoprotegerin.106
Moreover, hepatic FGF21 protein expression is
significantly induced in murine models of hep-
atocarcinogenesis and during hepatic stress in
humans.104 Increased hepatic FGF21 expression has
been observed in stage A HCC, NAFLD, cirrhosis and
hepatitis C, so its applicability as a marker for a
specific disease could be limited. Further studies on
FGF21 and its association with hepatic injury
beyond NAFLD and MetS are required.
Hepassocin
Hepassocin (HPS) (also known as hepatocyte-
derived fibrinogen-related protein 1) is a hep-
atokine that is involved in liver regeneration and is
induced by the hepatocyte nuclear factor 1a
(HNF1a)-regulated IL-6/IL-6R/STAT3 pathway in
hepatoma cells in vitro.107 High levels of serum HPS
were detected in mice and patients with NAFLD,
and levels of HPS correlated with NAS.108 Serum
HPS concentrations also correlated with those of
inflammatory cytokines (e.g. IL-1b, IL-6, TNF-a) and
the expression of lipogenesis-related markers
(FASN, ACC, SREBP-1). Hepatic overexpression of
HPS induced lipid accumulation through an extra-
cellular signal-regulated kinase 1/2 (ERK1/2)-
dependent pathway in mice.109 Additionally, HPS
has been shown to contribute to the development
of IR and T2DM through ERK1/2 activation in HPS
knock-out mice.110 HPS expression in BAT and liver
was increased following partial hepatectomy inJournal of Hepatology 2021 vol. 74 j 4mice110 and by IL-6 in vitro,107 suggesting a cross
talk between the injured liver and adipose tis-
sue.110 Oleic acid increased HPS expression by
activating signal transducer and activator of tran-
scription 3 (STAT3) signalling and inducing IR in
HepG2 cells,111 while palmitic acid induced HPS
through p38-modulated binding of C/EBPb to the
HPS promoter in mice.112 HPS administration pro-
tected against liver injury and improved survival in
rats with hepatitis.113 In contrast, liver-specific HPS
expression is repressed in HCC cells and patients
with HCC,107,114 likely through a decrease in HNF1a
expression.107,115 It remains to be elucidated if HPS
has protective effects on metabolic alterations in
the liver and adipocytes in NASH and NASH-related
HCC.
Retinol-binding protein 4
Retinol-binding protein 4 (RBP4) is a specific
retinol/vitamin A carrier protein belonging to the
lipocalin family. This plasma protein is primarily
synthesised in the liver but also released from ad-
ipose tissue as an adipokine.116 All-trans-retinol
binding induces RBP4 secretion, and vitamin A
deficiency causes RBP4 accumulation in human
liver.116,117 In turn RBP4 is released upon saturation
with retinol. In NAFLD, liver vitamin A homeostasis
is disrupted, which may contribute to disease
progression.118 Though the role of RBP4 in NAFLD
and IR is controversial, as has been reviewed
elsewhere.119 Some studies found no correlation
between liver and plasma RBP4 levels and NAFLD/
NASH severity,120–122 while others detected a cor-
relation between circulating RBP4 levels and
NAFLD development.123,124 In a large prospective
study, baseline RBP4 was positively associated with
the occurrence of NAFLD, and elevated levels of
serum RBP4 were detected in patients with
NAFLD.124,125 In NASH, high hepatic RBP4 protein
expression correlated with a moderate to severe
fibrosis score (>−F2, with a high NAS score) and high
lobular inflammation scores.126 RBP4 expression by
adipocytes may further contribute to IR and T2DM
in obesity.127,128 Both obese-non-diabetic and
obese-diabetic patients had 1.9-fold elevated
serum RBP4 levels compared to lean controls,127,128
and serum levels of RBP4 positively correlated with
BMI and IR.128 Conversely other reports showed
serum and hepatic RBP4 levels to negatively
correlate with liver fibrosis stage.121 While these
results seem inconclusive, they could be explained
by the pleiotropic functions of RBP4, the differ-
ences among NAFLD disease stages, and the char-
acteristics of the different populations studied. In
cirrhosis, RBP4 expression correlated with reduced
hepatic glucose production,129 but not with
IR.121,129–131 Impaired vitamin A homeostasis and
deficiency may also be seen in liver fibrosis and
cirrhosis.132
Collectively, the data suggests that RBP4 could






kines are important players
in the crosstalk between
liver and adipose tissue
and the pathophysiology of
NAFLD and NASH-related
HCC with or without
cirrhosis.from NASH with advanced fibrosis/cirrhosis or
NASH-related cirrhotic HCC. Further studies
controlling for the separate impact of IR and
fibrogenesis on RBP4 expression in the liver and
adipose tissue are required.
Adipokines
Adiponectin
Adiponectin is a key adipokine with important
metabolic functions including glucose regulation,
insulin sensitising, and fatty acid oxidation. Adi-
ponectin also has anti-inflammatory, anti-fibrotic,
and anti-tumourigenic activities37,46,133,134 and is
an important mediator of FGF21 activity.135 Circu-
lating levels of adiponectin negatively correlate
with BMI and are decreased in patients with
advanced NASH, IR, T2DM, and MetS.91,136–142 High
molecular weight (HMW) adiponectin, which is
thought to be the most biologically active form, has
been associated with IR, cardiovascular diseases,
and liver fibrosis in humans.140,143 HMW adipo-
nectin also inhibits the proliferation of HSCs in part
via the AMPK pathway in vitro.140,144,145 A recent
systematic review and meta-analysis showed that
serum adiponectin levels were decreased in pa-
tients with NAFL and NASH compared to controls,
and increased in NAFL compared to NASH, inde-
pendently of BMI, age, gender, and T2DM.140 By
now it is clear that adiponectin serum concentra-
tions are inversely correlated with BMI as well as
the severity of NAFLD (NAS), and low adiponectin is
associated with hepatic and systemic IR. Increased
adipose tissue mass in overweight and obesity,
reduced adiponectin, and IR are interconnected,
making it difficult to determine if reduced adipo-
nectin has an effect independent from obesity. That
said, a few studies demonstrating the effects of low
adiponectin on the severity of NAFLD or IR,146–149
and increased adiponectin levels under pioglita-
zone treatment (without any weight loss),150,151
hint to an effect of adiponectin independent of
BMI or adipose tissue mass.
In the liver, adiponectin activates the AMPK and
PPAR-a pathways, inhibits gluconeogenesis by
downregulating gluconeogenesis-related genes (i.e.
PEPCK, G6P, ACC, FASN, CPT-1), promotes FFA
oxidation, and suppresses lipogenesis.152 Proin-
flammatory cytokines such as TNF-a and IL-6 inhibit
adiponectin levels under conditions of oxidative
stress and hypoxia in vitro and in mice.153,154
Conversely adiponectin suppresses TNF-a in adipo-
cytes. Adiponectin also suppresses NF-jB activation,
TNF-a, and IL-6 inmurineNASHandHCCmodels and
in vitro.155,156 Adiponectin deficiencyenhancedhigh-
fat diet (HFD)-induced glucose intolerance and
obesity by increasing TNFa and FFA via down-
regulation of PPARa.157 In addition, hepatic TNF-a
expression was significantly increased in
adiponectin knock-out mice and, under HFD
conditions, adiponectin deficiency enhanced the
development of obesity, hyperlipidaemia,Journal osteatohepatitis, pericellular fibrosis, and adenoma
formation.158 These results suggest that adiponectin
has a protective role in NASH and liver fibrosis158 by
reducing IR.
Among patients with HCC, plasma adiponectin
levels were significantly lower than in non-HCC
controls and were also negatively correlated with
tumour size.159 In mice, the administration of
exogenous adiponectin inhibited liver tumour
growth and metastasis.159 A prospective case-
control study showed that levels of circulating
adiponectin, leptin, fetuin-A, C-reactive protein, IL-
6 and C-peptide were significantly increased in
patients with HCC compared to controls. Non-
HMW adiponectin, IL-6, C-reactive protein, C-pep-
tide and GLDH were associated with a higher risk
of non-viral HCC, independent of established liver
cancer risk factors and BMI.78 Elevated adiponectin
and leptin levels were also found among cirrhotic
and non-cirrhotic virus infected patients with
HCC.160–162 Serum adiponectin levels correlated
with the stage of liver fibrosis,163 were associated
with cirrhosis in patients with chronic liver dis-
eases,164 and with worsened overall survival in
patients with HCC.160,162,163 These results suggest
that serum adiponectin may be a useful parameter
to distinguish early stages of NASH (i.e., decreased
levels of adiponectin) from more advanced stages
such as liver cirrhosis and HCC (i.e., increased adi-
ponectin levels).91 Still, the role of adiponectin in
NASH-related HCC and non-cirrhotic NASH-HCC
requires further investigation.
Apelin
Apelin is an adipokine which is regulated by TNF-a
and by insulin in human adipocytes in vitro.165,166
Apelin contributes to the angiogenesis of liver tis-
sue in NASH at early stages167 and seems to stim-
ulate arteriogenesis in HCC in both humans and
mice.168 In addition, apelin promotes hepatic
fibrosis through ERK signalling in the human HSC
cell line LX-2.169 In patients with NAFLD, serum
apelin levels (with apelin-13 being the main form
circulating in plasma) were significantly higher in
obese patients.170,171 Plasma apelin-13 (13 aa), an
active fragment of pre-proprotein apelin (77 aa),
reduces the expression of lipogenic SREBP-1c and
increases lipolytic PPARa expression.172
In patients with HCC, apelin is further overex-
pressed and promotes HCC tumorigenesis.173,174
Evaluation of apelin and apelin receptor (APJR)
expression in 288 curatively resected HCCs
revealed that high APJR expression was signifi-
cantly associated with the presence of microvas-
cular invasion, intrahepatic metastasis, and early
recurrence independent of HCC aetiology.173 In
HCC, Wnt/b-catenin signalling induces apelin
expression, which correlates with upregulation of
phospho-Akt and phospho-glycogen synthase ki-
nase 3 b (GSK3b), thereby accelerating cell cycle




ANGPTLs, FGFs, and apelin,
are promising candidates
to improve detection,
diagnosis and treatment of
NAFLD-related HCC.
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Reviewthe mechanistic role of apelin in NASH-related HCC
as well as cirrhotic vs. non-cirrhotic HCC remains
unclear.
Chemerin
Chemerin, an adipokine as well as hepatokine, is
associated with obesity and MetS.175–177 Increased
circulating chemerin levels were significantly
associated with NAS and with hepatocyte
ballooning and inflammatory activity,178–180 while
chemerin expression in VAT was negatively asso-
ciated with NAS.181 Insulin regulates circulating
and adipocyte chemerin levels, which can be
decreased by treatment with metformin.182 Serum
levels of chemerin are significantly reduced after
weight loss and/or bariatric surgery.183 Chemerin
also induces FGF21 expression in primary human
hepatocyte cultures184 and, along with adiponectin
and fatty acid binding protein 4 (FABP4), levels of
serum chemerin exhibited strong associations with
components of MetS.185 However, results regarding
hepatic chemerin levels remain controversial:
while some studies showed that the hepatic
expression of chemerin is decreased in patients184
and mouse models of NASH,186 others reported
significantly elevated hepatic mRNA and protein
levels of chemerin as well as circulating chemerin
levels, and that these positively correlated with
BMI, hepatocyte ballooning, and the degree of he-
patic steatosis.180,187–189 This apparent discrepancy
may be related to differences in the patient cohorts
but requires clarification in sufficiently powered
studies.
In patients with HCC, there is a significant cor-
relation between low hepatic and serum chemerin
and poor prognosis.190,191 Low serum chemerin
levels correlate with hepatic dysfunction and
increased mortality in patients with decom-
pensated cirrhosis and ascites.192 Serum chemerin
negatively correlates with composite scores of
disease severity (Child-Pugh score, MELD and CLIF-
SOFA) in patients with mixed aetiologies.191,192 To
date, no human study has shown an impact of
chemerin in NASH-related HCC. In a single study in
mice, no changes in serum and/or hepatic chem-
erin levels were found in NASH-related HCC
compared to NASH.187 Thus, there is considerable
need for experimental and clinical research on the
role of chemerin in NASH-related HCC as well as on
its role in cirrhotic and non-cirrhotic HCC.
Leptin
Leptin is a regulator of appetite and energy
expenditure; it is probably the most prominent
adipokine, having been widely studied for many
years.193 By acting on the hypothalamus, leptin
decreases appetite and increases energy expendi-
ture via sympathetic stimulation of several tis-
sues.194 A recent review by Izquierdo et al.
summarised current knowledge on leptin and
leptin resistance in obesity195 and Adolph et al.Journal of Hepatology 2021 vol. 74 j 4reviewed the role of leptin in NAFLD-related HCC.46
Thus, we provide only a short overview of the
recent studies focused on leptin in NAFLD and HCC
with or without cirrhosis.
Obesity increases the expression and serum
levels of leptin, and leptin gene mutations result in
obesity in mice and humans.196,197 According to a
systematic review and meta-analysis by Polyzos
et al.,198 higher circulating leptin levels were seen
in NAFL and NASH compared to healthy controls,
and in NASH when compared to NAFL. Increased
serum leptin levels also correlated with increased
NAFLD severity,198 and a recent study further
showed that obesity and T2DM were associated
with increased leptin and decreased adiponectin
serum levels in patients with coronary artery dis-
ease.199 In addition, higher protein expression of
leptin and IL-6 in subcutaneous adipose tissue has
been observed in male patients with coronary ar-
tery disease.199
In patients with HCC, serum leptin levels are
increased and leptin expression significantly cor-
relates with tumour proliferation.200 Moreover,
increased serum leptin levels were found to be a
risk factor for recurrent stage I/II of HCC after
curative treatment.25 Serum leptin levels are
significantly increased in cirrhotic patients inde-
pendently of the presence of HCC201 and are not
associated with the development of HCC in
cirrhosis.201,202 However, leptin has a direct effect
on HSCs by increasing collagen gene expression
and stimulating activation of Stat3 in activated
HSCs.203 Therefore, it has been suggested that
leptin contributes to the progression of liver
fibrosis in NASH.204 Moreover, high circulating
leptin induces NADPH oxidase-NF-jB activation
and causes miR21-mediated SMAD7 inhibition
which increases transforming growth factor-b sig-
nalling and fibrogenesis in experimental and hu-
man NASH.205 Leptin has oncogenic potential and
stimulates the proliferation, tumour invasiveness
and migration of HCC cell lines200,206 and chol-
angiocarcinoma cells in vitro,207 while adiponectin
antagonises the oncogenic activity of leptin in
HCC.200 In addition, normal and malignant chol-
angiocytes express leptin and both long and short
isoforms of leptin receptors.199,207 Increased serum
leptin levels seem to be associated with carcino-
genesis in obesity.208
Taken together, in patients with obesity and
NAFLD, high serum leptin concentrations seem to
be associated with adverse disease course (fibro-
genesis and HCC development) as well as adverse
outcomes. New strategies to utilise leptin as a
marker for HCC development in NAFLD or even as a
therapeutic target in this setting should be
developed.
Resistin
Resistin is an adipokine related to inflammatory
responses by NF-jB-dependent stimulation of42–457
proinflammatory cytokines such as IL-1, IL-6,
IL-12, and TNF-a.209–211 In humans, resistin seems
to be synthesised mostly by mononuclear cells
within and outside the adipose tissue.210 Previ-
ously, circulating resistin was found to be signifi-
cantly elevated in morbidly obese (BMI >49)
patients212 and those with T2DM213 when
compared with healthy donors, but systemic
resistin levels did not correlate with IR.214 A more
recent study did not find any significant correla-
tion between resistin levels and BMI.214 While the
comparison of serum resistin levels in patients
with different NAFLD stages from various studies
was inconsistent,210 more recent studies showed
that serum, liver and VAT resistin levels were
decreased in patients with NAFLD after laparo-
scopic sleeve gastrectomy.215,216 Interestingly, liver
resistin expression significantly correlated with
NAS and the adipocyte size as well as VAT
inflammation.216 In patients with NASH, the serum
levels of resistin also showed an inverse correla-
tion with the stage of fibrosis.217 High resistin
levels (>12 ng/ml) were associated with HCV-
related cirrhosis and are considered an inde-
pendent risk factor for the development of
HCV-related HCC.218 However, the role of resistin in
NASH-related HCC has not yet been investigated.
Visfatin
Visfatin (also known as nicotinamide phosphor-
ibosyl transferase or Nampt), is an adipokine highly
expressed in epicardial adipose tissue of male pa-
tients with coronary artery disease.199,219 Plasma
visfatin levels are significantly elevated in patients
with NAFLD compared to healthy controls,220,221
and it has been suggested that plasma visfatin
concentrations might predict the presence of portal
inflammation in patients with NAFLD.222 However,
in NAFLD, visfatin expression did not correlate with
the NAS score and inflammatory stages, while vis-
fatin expression was significantly higher among
patients with fibrosis than non-fibrotic controls,
and even more pronounced in advanced fibrosis.223
Additionally, hepatic visfatin expression was
increased in morbidly obese patients with
T2DM.223 However, according to a recent long-
term follow-up study in a German population,
visfatin levels did not correlate with the presence
or absence of NAFLD at baseline, while there was a
strong correlation between serum visfatin levels
and leukocyte numbers, which indicates a poten-
tial proinflammatory role for visfatin.224
Increased visfatin is associated with poor
prognosis in patients with HCC,225,226 which is
underlined by its association with HCC progres-
sion.227 Significantly increased visfatin expression
was also seen in patients with cirrhosis compared
to controls.226 While increased plasma visfatin
levels were found in HCC due to viral hepatitis,228Journal othere is not yet conclusive evidence for a role of
visfatin in NASH-related HCC.
Specific role of hepatokines and
adipokines in non-cirrhotic NASH-related
HCC and clinical applicability
Up to now, very few studies have specifically
addressed the question of how a particular hep-
atokine or adipokine is involved in HCC develop-
ment in non-cirrhotic NASH, although we can
derive information on this topic from the data we
have compiled. The serum levels and hepatic
expression of FGF2, FGF21 and leptin are increased
in cirrhosis and HCC. Adiponectin is usually reduced
in obesity and even more so in NAFLD and NASH,
but seems to increase again during fibrogenesis.161
Very low adiponectin levels have been found in
HCC, however high serum adiponectin in HCC is
associated with poor survival (in HCV patients).
Thus, it is not currently possible to differentiate
between the effects of these factors on fibrogenesis/
cirrhosis and HCC development. This is also the case
for angiopoietins, hepassocin, apelin, resistin and
visfatin, which are either similarly regulated in
fibrogenesis/cirrhosis and HCC, or for which there
are insufficient data to unravel their effect on the
development of cirrhosis and HCC in NAFLD. In
contrast, FGF19 seems to be on the one hand
inversely correlated with fibrosis stage in patients
with alcohol-related liver disease229 and on the
other hand associated with increased HCC risk and
poor outcome. Awell-designed prospective study in
patients with NAFLD-related HCC, with and without
cirrhosis, would be needed to clarify the contribu-
tion of known hepatokines and adipokines to HCC
development in non-cirrhotic NAFLD.
The same is valid for the diagnostic and even
more so for the therapeutic application of hep-
atokines and adipokines. The effect sizes of
changes in serum concentrations during NAFLD
and HCC are probably too small for a single factor
to be used as a diagnostic marker for HCC. How-
ever, when measured sequentially over the course
of NAFLD, individual changes to a set of hep-
atokines and adipokines could possibly assist in the
identification of those at risk or in the process of
developing HCC. For example, reductions in serum
concentrations of ANGPTL1 and 4, and hepassocin,
in association with a pronounced fall in adipo-
nectin level might suggest HCC development.
Meanwhile, increases in the level of serum fetuin-
A, FGF2, 19, 21, in association with an even
greater increase in serum apelin and leptin levels
could indicate HCC development. The combination
of suppressed adiponectin but elevated chemerin
and visfatin levels could portend a poor prognosis
in NAFLD-related HCC. Overall, there is still insuf-
ficient evidence to utilise the potential of hep-
atokines and adipokines in clinical practice.f Hepatology 2021 vol. 74 j 442–457 451
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ReviewConclusion
The incidence ofNAFLD-relatedHCChas increased in
parallel with the obesity pandemic and the subse-
quent rise inNAFLDprevalence. Better screening and
diagnostic approaches are required to compensate
for the expected increase in NAFLD-related HCC
cases, while novel therapeutic options are war-
ranted. Hepatokines and adipokines have potential
as markers of disease progression in NAFLD or even
as earlymarkers forHCCdevelopment in this setting.
In particular, increases in serum ANGPTL1, 2, and 8,
FGF2,19, and21, apelin, chemerin, leptin, andvisfatin
have been associated either with HCC development
or a poor prognosis in NAFLD-related HCC.
Conversely, reduced serum concentrations of
ANGPTL4, hepassocin, and adiponectin were
observed in NAFLD-related HCC. These observations
provide hope for the possible development of an
NAFLD-HCC detection panel based on a combination
of hepatokines and adipokines. Deeper understand-
ing of the underlying mechanisms responsible for
increases or decreases in these factors in HCC
development might even uncover novel preventive
or therapeutic strategies.
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